BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28179176)

  • 1. Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response.
    Yusuf MB; Amsbaugh MJ; Burton E; Chesney J; Woo S
    World Neurosurg; 2017 Apr; 100():632-640.e4. PubMed ID: 28179176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
    Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases.
    Frakes JM; Figura NB; Ahmed KA; Juan TH; Patel N; Latifi K; Sarangkasiri S; Strom TJ; Chinnaiyan P; Rao NG; Etame AB
    J Neurosurg; 2015 Nov; 123(5):1261-7. PubMed ID: 26140482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes.
    Gabani P; Fischer-Valuck BW; Johanns TM; Hernandez-Aya LF; Keller JW; Rich KM; Kim AH; Dunn GP; Robinson CG; Chicoine MR; Huang J; Abraham CD
    Radiother Oncol; 2018 Aug; 128(2):266-273. PubMed ID: 29960685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent Radiosurgery and Immune Checkpoint Inhibition: Improving Regional Intracranial Control for Patients With Metastatic Melanoma.
    Murphy B; Walker J; Bassale S; Monaco D; Jaboin J; Ciporen J; Taylor M; Dai Kubicky C
    Am J Clin Oncol; 2019 Mar; 42(3):253-257. PubMed ID: 30557166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.
    Wegner RE; Abel S; D'Amico RS; Mehta GU; Sheehan J
    J Neurooncol; 2021 Mar; 152(1):79-87. PubMed ID: 33432380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS).
    Samlowski WE; Watson GA; Wang M; Rao G; Klimo P; Boucher K; Shrieve DC; Jensen RL
    Cancer; 2007 May; 109(9):1855-62. PubMed ID: 17351953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab.
    Cohen-Inbar O; Shih HH; Xu Z; Schlesinger D; Sheehan JP
    J Neurosurg; 2017 Nov; 127(5):1007-1014. PubMed ID: 28059663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation necrosis with stereotactic radiosurgery combined with CTLA-4 blockade and PD-1 inhibition for treatment of intracranial disease in metastatic melanoma.
    Fang P; Jiang W; Allen P; Glitza I; Guha N; Hwu P; Ghia A; Phan J; Mahajan A; Tawbi H; Li J
    J Neurooncol; 2017 Jul; 133(3):595-602. PubMed ID: 28500560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects.
    Diao K; Bian SX; Routman DM; Yu C; Kim PE; Wagle NA; Wong MK; Zada G; Chang EL
    J Neurosurg; 2018 Dec; 129(6):1397-1406. PubMed ID: 29303446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
    Ahmed KA; Freilich JM; Sloot S; Figura N; Gibney GT; Weber JS; Sarangkasiri S; Chinnaiyan P; Forsyth PA; Etame AB; Rao NG
    J Neurooncol; 2015 Mar; 122(1):121-6. PubMed ID: 25519302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic radiosurgery for the treatment of melanoma and renal cell carcinoma brain metastases.
    Lwu S; Goetz P; Monsalves E; Aryaee M; Ebinu J; Laperriere N; Menard C; Chung C; Millar BA; Kulkarni AV; Bernstein M; Zadeh G
    Oncol Rep; 2013 Feb; 29(2):407-12. PubMed ID: 23151681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases.
    Schapira E; Hubbeling H; Yeap BY; Mehan WA; Shaw AT; Oh K; Gainor JF; Shih HA
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):624-629. PubMed ID: 29678530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis.
    Lu VM; Goyal A; Rovin RA; Lee A; McDonald KL
    J Neurooncol; 2019 Jan; 141(1):1-12. PubMed ID: 30392086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
    Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
    J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone.
    Sawrie SM; Guthrie BL; Spencer SA; Nordal RA; Meredith RF; Markert JM; Cloud GA; Fiveash JB
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):181-6. PubMed ID: 17768015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases.
    Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL
    World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases.
    Selek U; Chang EL; Hassenbusch SJ; Shiu AS; Lang FF; Allen P; Weinberg J; Sawaya R; Maor MH
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1097-106. PubMed ID: 15234044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.